Literature DB >> 3485976

Separation of recombinant human interleukin-2 and methionyl interleukin-2 produced in Escherichia coli.

T Yamada, K Kato, K Kawahara, O Nishimura.   

Abstract

Escherichia coli harboring the gene coding for human interleukin-2 (IL-2) produced methionyl IL-2 (Met-IL-2) having an additional methionine residue at the amino terminus as well as IL-2 starting with the amino terminal alanine. IL-2 and Met-IL-2 were copurified from a cell-free extract. It was difficult to separate these two molecular species from each other because of the similarities of their physico-chemical characteristics. We found that the isoelectric points of IL-2 and Met-IL-2 were slightly but significantly different and succeeded in separating these two molecular species by utilizing the difference of their isoelectric points. The isoelectric points of IL-2 and Met-IL-2 thus obtained were determined to be 7.7 and 7.5, respectively. The in vitro specific activities of these two species were the same and similar to that of natural human IL-2 derived from peripheral blood lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485976     DOI: 10.1016/0006-291x(86)91004-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Characterization of human and mouse granulocyte-macrophage-colony-stimulating factors derived from Escherichia coli.

Authors:  J L Schrimsher; K Rose; M G Simona; P Wingfield
Journal:  Biochem J       Date:  1987-10-01       Impact factor: 3.857

2.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

4.  Purification and renaturation of recombinant human interleukin-2.

Authors:  M P Weir; J Sparks
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

5.  Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.

Authors:  S Hinuma; K Naruo; K Ootsu; T Houkan; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

6.  Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid.

Authors:  P H Hirel; M J Schmitter; P Dessen; G Fayat; S Blanquet
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.

Authors:  Y Sakura; K Ootsu; A Shino
Journal:  Jpn J Cancer Res       Date:  1989-09

8.  Antitumor effect of recombinant human interleukin-2 on the growth of murine hemangioendothelioma D14 in nude mice: occurrence of large granular cells in the tumor.

Authors:  Y Sakura; T Houkan; K Ootsu; A Shino
Journal:  Jpn J Cancer Res       Date:  1991-08

9.  Lysis of human leukemic cells by monocyte-derived macrophages activated with interferon-gamma and interleukin-2.

Authors:  T Kakita; M Sasada; T Moriguchi; T Nishimura; K Yamamoto; H Uchino
Journal:  Jpn J Cancer Res       Date:  1989-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.